Megan Kruse, MD, Discusses the Use of Biosimilars in Breast Cancer Treatment
The hematology and medical oncology expert described the implementation of biosimilars into treating patients with breast cancer.
Related Articles
Lung Cancer Screening Adherence Decreases Across Subsequent Testing
Findings from a multicenter cohort study support screening adherence as a key lung cancer screening quality metric.
FDA Clears IND for VS-7375 in KRAS G12D-Mutated Advanced Solid Tumors
The clearance precedes the initiation of a phase 1/2a trial that will evaluate the efficacy and safety of VS-7375 in advanced solid tumors with a…
100 Non-Pharmacological Interventions for Managing Abemaciclib-Associated Adverse Events in Patients With Early/Advanced HR+/HER2– Breast Cancer: A US-Based Health Care Provider Survey
Home to the journal Oncology, Cancer Network provides research and opinion on the screening, early detection, diagnosis, treatment, and prevention of cancers.
Pharmacist Video Consultations May Reduce Polypharmacy in Cancer Care
Polypharmacy, medication list errors, and drug-drug interactions were all observed in patients with cancer receiving oral anticancer drugs.
SWOG 80702: Impressions on the Efficacy Data
Panelists discuss how the efficacy data from SWOG 80702 demonstrated that shortened duration of adjuvant chemotherapy (3 months vs 6 months) yielded comparable survival outcomes…
Navigating Prognosis and Treatment Goals in Upper GI Cancer: A Patient- and Family-Centered Approach
Experts discuss how to approach prognosis and treatment goals with a patient, considering their family history of gastric cancer and advanced-stage disease.
Tislelizumab Significantly Boosts Survival in Lung Cancer Trials
A systematic review shows that well-designed randomized clinical trials are necessary to optimize treatment strategies with tislelizumab in lung cancer.
TTFields Therapy Earns EU Approval in Metastatic Non–Small Cell Lung Cancer
Data from the phase 3 LUNAR trial support the Conformité Européenne Mark for tumor treating fields in metastatic non–small cell lung cancer.
Ivonescimab/Chemo Prolongs PFS in 1L Advanced Squamous NSCLC
The phase 3 HARMONi-6 trial found invonescimab plus chemotherapy improved PFS vs tislelizumab plus chemotherapy in squamous NSCLC.
New Legislation May Help Reduce Extravasation Rates in Cancer Radiology
Modifying injection methods when administering radioactive therapies may significantly reduce extravasation rates.